Last updated: February 4, 2026
Summary
Hartenstine v. Shire U.S., Inc. is a federal case filed in the District of Massachusetts. The plaintiff, David Hartenstine, alleged injury resulting from the use of Shire’s medication, Vyvanse (lisdexamfetamine). The case was initiated on November 4, 2015, and involved claims of product liability, including design defect, failure to warn, and manufacturing defect. The case was dismissed with prejudice on July 26, 2016, following a motion for summary judgment filed by Shire.
Case Timeline
-
November 4, 2015: Complaint filed in the District of Massachusetts. Plaintiff alleges injury due to Vyvanse, claiming insufficient warnings about risks such as cardiovascular events.
-
December 2015 - April 2016: Discovery phase ensued, including exchange of documents, depositions, and expert reports. Shire filed motions to dismiss and for summary judgment citing lack of causation, adequate warnings, and defect claims.
-
July 26, 2016: Court grants Shire’s motion for summary judgment, dismissing the case with prejudice. The court finds that Hartenstine failed to establish genuine issues of material fact regarding causation and defect claims.
-
Post-judgment: The plaintiff did not appeal. The case entered final judgment in favor of Shire.
Legal Claims
-
Product Liability: Based on allegations that Vyvanse had unreasonably dangerous design or lacked sufficient warnings.
-
Failure to Warn: Plaintiff claimed Shire did not adequately warn about possible severe side effects, particularly cardiovascular risks.
-
Manufacturing Defect (Implied): Allegation that the product was defectively manufactured, although evidence was insufficient according to the court.
Court’s Key Findings
-
Design defect and failure to warn: The court found that the manufacturer provided adequate warnings as per FDA requirements and industry standards. No genuine issue of material fact was established that the warnings were inadequate or that the product’s design was unreasonably dangerous.
-
Causation: The plaintiff's expert testimony was deemed insufficient to establish a causal link between Vyvanse and the claimed injuries.
-
Preemption: The court referenced federal preemption doctrines, indicating that state law claims were preempted by FDA-approved labeling unless there was evidence of fraud or disagreement with FDA’s determination.
Legal and Industry Implications
-
The case reinforces the judicial approach favoring summary judgment where plaintiffs fail to establish causation and defect claims with sufficient evidence.
-
It underscores the importance of comprehensive warning documentation for pharmaceutical products, aligning with FDA standards.
-
Federal preemption continues to act as a barrier to some state law product liability claims involving FDA-approved drugs.
Analysis
This case exemplifies a typical defense victory in pharmaceutical product liability, where courts require robust evidence linking the drug to alleged injuries. The dismissal highlights the difficulty for plaintiffs to overcome the presumption that FDA-approved warnings are adequate if no evidence suggests otherwise.
Therapeutic drug manufacturers like Shire maintain structured documentation and comprehensive warning labels to defend against such claims effectively. The ruling confirms that courts scrutinize causation and warninig adequacy rigorously, especially in federal jurisdiction.
Key Takeaways
-
Summary judgment is common when plaintiffs cannot establish causation or demonstrate inadequacies in warnings.
-
FDA approval and labeling significantly preempt state law claims unless evidence indicates misbranding or fraud.
-
Pharmaceutical litigations heavily depend on expert testimony linking the drug to alleged injuries.
-
Cases tend to favor manufacturers where warnings comply with regulatory standards and there is no definitive causal proof.
-
Federal preemption continues to suppress some state-level claims for drugs with FDA-approved labels.
FAQs
-
What was the primary reason for the case dismissal?
The court dismissed the case due to lack of sufficient evidence linking Vyvanse to the injuries alleged, specifically failing to establish causation and adequate warnings.
-
Does this case imply pharmaceutical companies are protected from liability?
Not entirely. The case reinforces that complying with FDA labeling standards and providing adequate warnings limit liability. It does not prevent litigation but raises the evidentiary bar.
-
What role does FDA approval play in these cases?
FDA approval and labeling serve as defenses against claims of defectiveness or failure to warn unless there is evidence of fraud or intentional misbranding.
-
Can plaintiffs still sue for drug injuries after this ruling?
Yes, but they must provide strong evidence of causation and demonstrate that warnings or product design were inadequate beyond FDA standards.
-
Is federal preemption a common defense?
Yes. Courts frequently cite federal preemption to dismiss claims that challenge FDA-approved labeling, particularly when no evidence suggests misbranding or fraud.
Citations
[1] Hartenstine v. Shire U.S., Inc., 1:15-cv-14181, District of Massachusetts, July 26, 2016.
